Olema Pharmaceuticals, Inc. OLMA R2KR3KPHARMA
Company Overview
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +103.98% |
| 6 Months: | -50.12% |
| 3 Months: | +4.27% |
| 1 Month: | -8.90% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.18 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 70.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OLMA Olema Pharmaceuticals, Inc. R2KR3KPHARMA | 10.75 | -5.30 | $938.99M | 0.00% | -37.10% | -42.86% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -1.04M | -2.49M | -7.87M | -15.45M | -16.52M | -17.76M | -23.25M | -33.29M | -23.22M | -29.60M | -21.60M | -23.34M | -34.34M | -33.53M | -37.62M | -34.87M | -47.86M | -45.88M | -57.99M |
| Net Income | -1.69M | -2.45M | -7.84M | -15.34M | -16.41M | -17.71M | -23.03M | -32.86M | -22.72M | -28.29M | -20.09M | -21.50M | -30.97M | -30.38M | -34.55M | -30.39M | -43.78M | -42.22M | -53.09M |
| Diluted EPS | - | -0.95 | -3.71 | -0.39 | -0.42 | -0.45 | -0.58 | -0.82 | -0.57 | -0.70 | -0.49 | -0.48 | -0.56 | -0.54 | -0.60 | -0.36 | -0.51 | -0.49 | -0.52 |
| R&D Expense | 795.00K | 1.95M | 4.67M | 10.69M | 11.91M | 12.52M | 16.01M | 27.05M | 17.63M | 22.83M | 17.99M | 19.45M | 29.88M | 29.11M | 33.23M | 30.62M | 43.90M | 39.95M | 49.23M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income | -4.32M | -21.53M | -71.49M | -106.99M | -104.96M | -142.26M | -178.70M |
| Net Income | -4.32M | -22.12M | -71.10M | -104.79M | -96.66M | -129.47M | -162.45M |
| Diluted EPS | -1.66 | -3.42 | -1.80 | -2.62 | -2.14 | -2.20 | -1.87 |
| R&D Expense | 3.92M | 13.70M | 51.10M | 82.27M | 86.14M | 124.52M | 157.70M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 342.72M | 295.94M | 215.65M | 276.94M | 450.98M | 533.43M |
| Total Equity | -8.40M | -10.59M | 338.14M | 284.57M | 197.55M | 253.90M | 408.96M | 478.56M |
| Cash & Equivalents | - | - | 338.55M | 13.81M | 23.70M | 68.54M | 139.48M | 48.30M |
| Total Liabilities | - | - | 4.58M | 11.38M | 18.10M | 23.05M | 42.02M | 54.87M |
| Current Liabilities | - | - | 4.58M | 9.02M | 16.55M | 21.62M | 41.76M | 51.80M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.08M | -19.87M | - | -82.06M | -83.73M | -104.35M | -146.72M |
| Investing Cash Flow | - | -56.00K | - | 91.48M | -4.85M | -93.53M | -155.76M |
| Financing Cash Flow | - | 358.40M | - | 476.00K | 133.41M | 268.82M | 211.30M |
| Capital Expenditure | - | -56.00K | -1.57M | -363.00K | - | -159.00K | - |
| Free Cash Flow | - | -19.92M | - | -82.43M | -83.73M | -104.51M | -146.72M |
| Net Change in Cash | - | - | - | 9.89M | 44.84M | 70.94M | -91.18M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 40.7% | -6.5% | -25.0% | -53.0% | -38.1% | -31.7% | -33.9% |
| ROCE % | - | -6.4% | -24.9% | -53.7% | -41.1% | -34.8% | -37.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 13.88% | 12.14M | $124.71M |
| 2 | Paradigm Biocapital Advisors LP | 9.91% | 8.67M | $89.05M |
| 3 | Jupiter Topco LLC | 8.11% | 7.09M | $72.86M |
| 4 | Bain Capital Life Sciences Investors, LLC | 8.10% | 7.09M | $72.77M |
| 5 | Blackrock Inc. | 7.67% | 6.71M | $68.96M |
| 6 | BVF Inc. | 6.05% | 5.30M | $54.39M |
| 7 | Siren, L.L.C. | 5.55% | 4.86M | $49.88M |
| 8 | State Street Corporation | 4.93% | 4.32M | $44.33M |
| 9 | Vanguard Capital Management LLC | 3.82% | 3.34M | $34.31M |
| 10 | Logos Global Management LP | 3.67% | 3.21M | $32.96M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OLMA
Readystate Asset Management LP Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxNWUxMOHN1MjZ6anBEMENZTjR3VVFBTkFrRHc0eWpDcGFMSC1WYW9rMFhkNjFWUHd4T0xxYXFfc2JkMnNvT2h5VTBJbkd4RzZFTlJHOExZUjZhTDR6WDB3MmZBei1laERXeV8xYkdhQUxSRjlxU2V2aE1FdEtrSGRnNHd1NTZ0dVZQbnF5Yk…
(OLMA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPQ3l0RG4zMFgzUDJ4SW9DeE56RmFaaWxkVHNKaF85akNwM1ZHeFlvblZrMW9YYzdDc1ZvSGF6QnF4a0RJNWh3RWtzcVJVSFlRS2xxUV9jRjRsdHFlUm1QMFVCd0JPSzVSTE5oc0NONHlpMWJnbEhVV19xWlhWdXFMY3BwYzJBUDVHUGlYSz…
A new finance chief gets options on 650,000 Olema shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOWHUwLWlXYjQ1WEw0SjZZLUxVeFg1enN5TjdmU3J2RTFwa1p4MDNBdTBwakY0dm5fY0pPNEY5a1hWWGgwOWU5b2NtQ1ZZUl94eWY4OUhaOThnOEllcUZfcExvY1JERGREbVNxMi01Q195X2Zsdl9IUHdfbGhPcVJNNm5EbXlMZGFMb196NF…
Olema Pharmaceuticals Grants Inducement Stock Options to Newly Appointed CFO Jason V. O’Byrne - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQZDFRQkcyVWotWmZtSDI5eEt6RTdOOFNkQkFZYWNyMHR4TmppVm53TkQwYUh4Y25xdnVnNm1Nd1RSVjhhMEpOVUp4TzREQmpkTDRPbGV6YVVzdGxKQmYwY1dLY1VZbnpWR2pCSk92cTU0NVVlLWVLT29hNkViaE1laG5vYUxIN1lMdXhEdV…
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQcnBMVkV2YXNJWTlvbE9ja0FMY0RnLThneUNFRDlRZzBDZEJCcE5xQmQ3NlZQZUxOMFBfX0ZnVUhpc3dRM2xWYUFKQXFrdnJHY29RdzBIQ1RWajFDSUlFaTk2aWJEbUJXZGNneGxpQW9XWVU3OHNPdUlIM0xIV0lTN2VtZmx3U1JW?oc=5"…
Bank of New York Mellon Corp Invests $2.78 Million in Olema Pharmaceuticals, Inc. $OLMA - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxOMURYeGFUblVya2ZnTVdKa0pSZlllTEczcG9PTkQ5VkVzRzNRa0xyRzZIbnlMYldFZ2xYNDR6UzlLMURiX3A1RDA3UjlMb3Rwd2lySmx2dXAyUFRvdWoyQktCdjdLaE5iaWxVVFYwUVhVenEtT19fTHoxNzFGTnlfeGt2ai01VG1VcnZJYW…
OLMA — Frequently Asked Questions
What is the current share price of Olema Pharmaceuticals, Inc. (OLMA)?
As of 2026-09-07 16:24 PDT, Olema Pharmaceuticals, Inc. (OLMA) trades at $10.75 on NasdaqGS. Its 52-week range is $5.26 to $35.83.
What is the market capitalisation of OLMA?
Olema Pharmaceuticals, Inc. (OLMA) has a market capitalisation of $938.99M on NasdaqGS.
What is the P/E ratio of OLMA?
OLMA trades at a trailing price-to-earnings (P/E) ratio of -5.30. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.19.
What is the return on equity (ROE) of OLMA?
OLMA has a return on equity (ROE) of -42.86%. Its return on capital employed (ROCE) is -37.10%.
Is OLMA a good stock to buy?
This page provides a data-driven analysis of Olema Pharmaceuticals, Inc. (OLMA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.